Skip to main content

Facioscapulohumeral Muscular Dystrophy clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Showing trials for
  • RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

    Orange, California and other locations